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Abstract: Glucocorticoids (GCs) are frequently used in anticancer 
combination regimens; however, their continuous use adds selective 
pressure on cancer cells to develop GC-resistance via impairment of the 
glucocorticoid receptor (GR), therefore creating a need for GC-
alternatives. Based on the drug repurposing approach and the 
commonalities between inflammation and neoplasia, drugs that are either 
in late-stage clinical trials and/or already marketed for GC-refractory 
inflammatory diseases, could be evaluated as GC-substitutes in the 
context of cancer. Advantageously, unlike new molecular entities 
currently being de novo developed to restore GC-responsiveness of cancer 
cells, such drugs have documented safety and efficacy profile, which 
overall simplifies their introduction in clinical cancer trials. In this 
study, we estimated the potential of a well-established, multistage, cell 
line-based, mouse skin carcinogenesis model to be exploited as an initial 
screening tool for unveiling covert GC-substitutes. First, we categorized 
the cell lines of this model to GC-sensitive and GC-resistant, in 
correlation with their corresponding GR status, localization and 
functionality. We found that GC-resistance starts in papilloma stages, 
due to a dysfunctional GR, which is overexpressed, DNA binding-competent, 
but transactivation-incompetent in papilloma, squamous and spindle stages 
of the model. Then, aided by this tool, we evaluated the ability of N-
bromotaurine, a naturally-occurring, small-molecule, NSAID which is under 
consideration for use interchangeably/in replacement to GCs in skin 
inflammations, to restore antiproliferative response of GC-resistant 
cancer cells. Unlike GCs, N-bromotaurine inhibited cell-cycle progression 
in GC-resistant cancer cells and efficiently synergized with cisplatin, 
thus indicating a potential to be exploited instead of GCs against 
cancer. 
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ABSTRACT 
Glucocorticoids (GCs) are frequently used in anticancer combination regimens; however, 
their continuous use adds selective pressure on cancer cells to develop GC-resistance via 
impairment of the glucocorticoid receptor (GR), therefore creating a need for GC-alternatives. 
Based on the drug repurposing approach and the commonalities between inflammation and 
neoplasia, drugs that are either in late-stage clinical trials and/or already marketed for GC-
refractory inflammatory diseases, could be evaluated as GC-substitutes in the context of 
cancer. Advantageously, unlike new molecular entities currently being de novo developed to 
restore GC-responsiveness of cancer cells, such drugs have documented safety and efficacy 
profile, which overall simplifies their introduction in clinical cancer trials. In this study, we 
estimated the potential of a well-established, multistage, cell line-based, mouse skin 
carcinogenesis model to be exploited as an initial screening tool for unveiling covert GC-
substitutes. First, we categorized the cell lines of this model to GC-sensitive and GC-
resistant, in correlation with their corresponding GR status, localization and functionality. We 
found that GC-resistance starts in papilloma stages, due to a dysfunctional GR, which is 
overexpressed, DNA binding-competent, but transactivation-incompetent in papilloma, 
squamous and spindle stages of the model. Then, aided by this tool, we evaluated the ability 
of N-bromotaurine, a naturally-occurring, small-molecule, NSAID which is under consideration 
for use interchangeably/in replacement to GCs in skin inflammations, to restore 
antiproliferative response of GC-resistant cancer cells. Unlike GCs, N-bromotaurine inhibited 
cell-cycle progression in GC-resistant cancer cells and efficiently synergized with cisplatin, 
thus indicating a potential to be exploited instead of GCs against cancer.  
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INTRODUCTION 
 Glucocorticoids (GCs) are steroid hormones which inhibit tumor cell proliferation, 
mitigate chemotherapy side effects and enhance efficiency of anticancer agents1,2. They are 
frequently included in combination anticancer therapies, either as palliative agents against 
chemotherapy-induced-nausea-and-vomiting or as antiproliferative agents. Their effects are 
mediated by the glucocorticoid receptor (GR). GC binds to GR which, following dissociation 
from a cytoplasmic chaperone/co-chaperone complex, translocates to the nucleus, 
homodimerizes and regulates gene expression. GR transactivates or transrepresses genes 
by direct binding to GREs (glucocorticoid responsive elements), by tethering itself to other 
transcription factors apart from DNA binding, or in a composite manner by both direct GRE 
binding and interactions with transcription factors bound to neighboring sites (reviewed by 
Ramamoorthy et al2). Thus, a functional GR elicits tumor-suppressive events in a pleiotropic 
manner, through a plethora of mechanisms and crucial pathways.3-5 
Theoretically, the clinical benefits demonstrated by the long-term experience on GCs, 
combined with the tumor-suppressive nature of GR, offer a strong alibi for their routine use in 
cancer therapeutics (e.g. prostate cancer, breast cancer, leukemia), as evidenced by the 
increasing number of GC-containing combination regimens, both established and 
investigational. Nevertheless, GC cotreatment often induces resistance towards cancer 
therapy1,6 thus raising concerns regarding the tendency of GC-sensitive cancer cells to 
develop resistance upon frequent GC use. Mechanistically, this tendency is attributed to the 
pleiotropic nature of GR per se. GR’s pleiotropy becomes a double-edged sword, since 
cancer cells have, at their disposal, as many potentials to overcome GR’s antiproliferative 
barrier and achieve GC-resistance, as is the plethora of underlying GR-mediated 
antiproliferative pathways they can defuse one way or another. For neutralizing GR 
antiproliferative effects, cancer cells exploit several strategies, which in several cases 
simultaneously co-exist in a cancer cell (e.g. reduced GR expression, reduced DNA binding 
ability, GR mutations and polymorphisms, co-expression of dominant negative GR isoforms, 
impairment of transrepression mode et.c.).2,7,8 GC-unresponsiveness by GR impairment may 
start as early as the benign stages, highlighting that inactivation of GC/GR axis is a selective 
advantage in order for a cancer cell to surpass the antiproliferative break and continue its 
tumorigenic march towards aggressive stages.9 
This overall necessitates alternatives restoring and/or surrogating for GCs’ 
antiproliferative effects.2,10 To this end, innovative synthetic molecules are being developed 
by academia, aiming to re-activate GR-mediated antiproliferative pathways and restore GC-
responsiveness of cancer cells10. If they successfully pass clinical trials, they will eventually 
find their way to the bedside. But this established bench-to-bedside pipeline is not an one-
way street. The recently framed concept of drug repurposing suggests evaluating suitability of 
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known drugs for use in new indications11. Implementing this concept in the issue of GC-
resistance, we postulate that drugs which are already in late stages of clinical trials or 
approved for indications other than cancer may be latent GC-substitutes, able to imitate 
aspects of the GC therapeutic profile. These hypothetical latent GC-substitutes might be 
competent to either restore the antiproliferative phenotypes in GC-resistant cells; or to be 
used interchangeably to GCs, in order to reduce the selective pressure exerted by continuous 
use of GCs on GC-sensitive cells, thus preventing/delaying their clonal expansion to GR-
impaired and, hence, GC-resistant cells. A clinical advantage of the proposed approach is 
that these candidate substances are actually closer to the bedside than they are to the bench, 
since they have a more characterized efficacy and safety profile, in terms of their 
documentation for other therapeutic indications. This is translated to both faster filing and 
regulatory approval procedures and to reduced financial costs to develop these substances 
as anticancer agents, compared to starting the anticancer drug research-and-development 
workflow from scratch, i.e. by developing New Molecular Entities (NMAs, defined by FDA as 
experimental substances without precedent among regulated and approved drug products).11 
Except for anticancer agents, GCs are also common anti-inflammatory agents. In fact, 
their use against inflammations historically preceded their use against neoplasias. GC-
resistance is a frequent problem in inflammations as well, and drugs are being developed in 
replacement of GC-containing anti-inflammatory regimens.12 Emerging GC-substitutes that 
are currently in the investigational clinical setting for inflammation management include, but 
are not limited to, the NSAID (Non-Steroid Anti-Inflammatory Drug) taurine haloamine 
derivatives, mainly N-bromotaurine (BrTaur) and N-chlorotaurine (ClTaur). These are 
generated by eosinophils and neutrophils at a site of inflammation and exert potent anti-
inflammatory properties. Other common features shared with GCs is their naturally-occurring 
and small-molecule nature and their immunomodulatory and antimicrobial properties13. 
Another common characteristic is the potential to ameliorate chemotherapy-induced nausea 
and vomiting, since their maternal substance, i.e. the non-essential aminoacid taurine, which 
is orally administered as a pro-drug in order to be converted to the haloamine derivative at 
the site of inflammation, was recently proven clinically capable of such an effect in leukemic 
patients.14 Advantageously, taurine haloamines have shown good efficacy, tolerance and 
insignificant toxic effects upon topical use on clinical patients who are refractory to 
conventional GC-based anti-inflammatory therapies13,1516. Based on the association between 
chronic inflammatory diseases and neoplasias,17,18 we postulated that a drug which exerts 
overlapping features and common therapeutic indications with GCs and is able to surrogate 
for GCs in GC-resistant inflammations may be able to surrogate for the GCs’ antiproliferative 
function in GC-resistant cancer cells as well.  
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As a springboard for testing this hypothesis, we took advantage of our long-term 
experience on a well-established mouse model of skin carcinogenesis.19 This comprises of a 
series of cell lines which represent different stages of mouse skin tumor progression and are 
categorized on the basis of increasing aggressiveness to immortalized keratinocytes (C5N), 
benign papillomas (P6), malignant squamous carcinomas (B9), and highly invasive spindle 
cells (A5, CarB).19 The B9:A5 pair represents the clonal expansion from squamous to spindle 
stages. The model has been developed in Dr. A. Balmain’s lab and has been thoroughly 
reviewed18 and described previously.20 Briefly, in order to obtain these cell lines, each of 
which represent the initiation, promotion or progression stages of skin carcinogenesis, a 
chemical carcinogenesis protocol on mice was applied. The normal epidermis of mice or 
normal epithelial mouse cells were treated with a single dose of the polycyclic aromatic 
hydrocarbon 7,12 dimethylbenz[a]anthracene (DMBA), followed by weekly applications of the 
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). This led to the development of 
numerous benign papillomas, some of which progressed to malignant squamous cell 
carcinomas several weeks after the first exposure to carcinogens and cell lines were 
produced from these tumors. Overall, this model poses the following advantages: a) it is 
multistage, meaning that it simulates the step-wise manner by which a tumor initiates, 
promotes and progresses, b) it is coherent, since cell lines have been derived in a consistent 
manner following a meticulous chemical carcinogenesis protocol, c) although skin-tissue 
based, it further applies to almost all epithelial cancers.21 Furthermore, the fact that the model 
is skin tissue-based facilitates our analysis, because skin cancer is a traditional field where 
the mechanisms of GR function in correlation to GC-responsiveness have been adequately 
studied.4,5,9 Therefore, although our model has never been characterized before in terms of 
GC-responsiveness, it stood a good chance to faithfully mirror or even complement previous 
robust findings.   
First, we characterized our system in terms of antiproliferative response to GCs. Then, we 
correlated this responsiveness to the underlying GR expression status, localization and 
functionality. Finally, we checked the ability of BrTaur to bypass GC-resistance of cancer cells 
either alone or in combination with cisplatin.  
 
 
MATERIALS AND METHODS 
Cells and culture conditions  
Mouse cell lines of the mouse skin carcinogenesis model have been produced and obtained 
by Dr. Allan Balmain. All human cell lines used were obtained by American Type Culture 
Collection (ATCC). Cells were cultured as previously described.22 The preparation23 and use 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
of BrTaur is covered by licensing agreement. The in-house formulation was donated by 
NASCO AD Biotechnology Laboratory for preclinical research purposes.  
 
Proliferation assays 
Collectively, 2250 cells per well were seeded in 96-well plates. After cells were attached, the 
first measurement was taken. This time point is called 0 hours. At this point, 24h after 
seeding, dexamethasone (10-9 – 10-6M, from a stock of 10-3M dexamethasone diluted in 
ethanol) , BrTaur (25μM-250μM from a stock of 4mM BrTaur) or taurine (5-50mM from a 
stock of 200mM taurine diluted in water) was added and measurements were taken after 24, 
48 and 72h. For co-treatment experiments, cells were treated with either 10-7M 
dexamethasone or BrTaur (125, 250 or 500μM) 24-hours prior, con-currently with or 24-hours 
post cisplatin treatment. Untreated cells were used as controls. Following treatments, cells 
were fixed with 100% methanol and, then, crystal violet solution was added to each well. After 
a 10-minute incubation in room temperature, each well was washed 3 times with 200μL 
water, and plates were incubated on a shaker for 45min. Optical Density (OD) was measured 
at 595nm using a Tecan reader. The data was transferred to Microsoft Excel and analyzed. 
Background absorbance was corrected using triplicate sets of wells containing medium only 
(no cells) and crystal violet reagent as per experimental well. Τhree independent experiments 
were performed and each one of them included a triplicate value set.  
 
RNA extraction, cDNA synthesis and qRT-PCR analysis 
mRNA extraction, cDNA synthesis and quantitative real-time PCR was conducted as 
previously described.24 Primers used appear in Table I.  
 
Preparation of cell lysates and Western blot analysis 
Total, cytoplasmic and nuclear cell lysates were prepared as previously described.25 The 
primary antibody was an in-house anti-GR rabbit polyclonal antibody, clone 2F8, against 
aminoacids 305-427 of the N-terminal domain (kindly provided by Dr. M.N. Alexis), in a 1:500 
dilution. Primary anti-beta-actin antibody in a 1:1000 dilution was used as a loading control. 
The secondary antibody was a mouse anti-rabbit antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) in a 1:1000 dilution. 
 
Two-stage chemical carcinogenesis protocol 
Tumors induced on mouse skin following a chemical carcinogenesis protocol were fixed and 
paraffin-embedded. Slides carrying formalin-fixed paraffin-embedded (FFPE) mouse skin 
papilloma and squamous and spindle tumors were prepared as previously described.22 In 
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vivo experiments were performed in the in-house authorized animal house. Experiments 
complied with the Protocol on the Protection and Welfare of Animals, as obliged by the rules 
of the National Hellenic Research Foundation, the regulations of the National Bioethics 
Committee and the article 3 of the presidential decree 160/1991 (in line with 86/609/EEC 
directive) regarding the welfare of experimental animals. 
 
Immunohistochemical and immunocytochemical staining 
Immunohistochemical staining on FFPE sections was performed as described earlier.26 The 
sections were stained with anti-GR, clone 2F8, in a 1:10 dilution. For the 
immunocytochemistry staining with anti-GR antibody 2F8, we followed the same procedure, 
incubation periods and reagents, by omitting the deparaffinization step.  
 
Immunofluorescence staining 
Cells were grown and fixed on coverslips and where subjected to immunofluorescence 
staining as previously described.27 The slides were incubated with primary antibody anti-GR, 
clone M-20 (Santa Cruz Biotechnology, Santa Cruz, CA) in a 1:50 dilution. The secondary 
antibody was anti-rabbit FITC-conjugated (Jackson Laboratory, Bar Harbor, Maine, USA) 
diluted in 1:100.  
 
Electrophoretic Mobility Shift assay 
Annealed oligonucleotides for the human metallothionin IIA Glucocorticoid Responsive 
Element (5’-TGGTACACTGTGTCCTGAATTCA-3’ and 5’-
TGAATTCAGGACACAGTGTACCA-3’) were end-labeled with γ32P-ATP using T4-
polynucleotide kinase and the reaction products were purified on a 8% polyacrylamide gel. 
DNA binding reactions were performed as previously described.28 For the supershift control 
experiment, the primary polyclonal antibody anti-GR 10-10 (kindly provided by Dr. M. Alexis) 
was used. 
 
Plasmids, transfections and luciferase reporter assay 
A luciferase plasmid carrying GRE sequences (17m-GRE-G-Luc), as well as a control vector 
carrying no GRE binding site (tata-pG13Luc) described previously29 were used for 
transfections. Where indicated, cells were incubated with dexamethasone and transfected 
with by the calcium phosphate method, as described previously7. The luciferase activity was 
measured using a luminometer and was normalized for transfection efficiency with the β-
galactosidase activity.  
 
FACS analysis 
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Cells were harvested, trypsinized and centrifuged at 1,000rpm for 5min, at room temperature. 
The pellet was resuspended in 500μL PBS, fixed with 80% ethanol, vortexed, and stained 
with propidium iodide (50μg/mL), in the presence of 5mmol/L MgCl2 and 10μg/mL RNase A in 
10mmol/L Tris-HCl (pH 7.5). DNA content was analyzed on a FACSCalibur (Becton 
Dickinson) using the Modfit software. 
 
Statistical analysis 
Data are expressed as mean±SD. Each experiment was performed in triplicates. Τhen, the 
triplicate set values of three independent experiments were analyzed. For statistical analyses 
of proliferation assays resultsexperiments,  ANOVA utilising Dunetts’ T3 post-hoc analysis the 
student's t-test was applied. QPCR results were evaluated using Mann-Whitney’s test. 
Luciferase assays were analyzed using independent student’s t-tests. P values of less than 
0.05 were considered significant. 
 
 
RESULTS 
The antiproliferative effect of GCs is lost in the promotion and progression stages of 
mouse skin carcinogenesis 
Our first priority was to explore the GC antiproliferative effect on the cell lines of our system. 
GC effect ranges from proliferative in very low concentrations, to cytostatic/antiproliferative in 
more physiological concentrations and cytotoxic/apoptotic in higher concentrations.30 To 
monitor GC effect on our system, we treated cells with a range of dexamethasone 
concentrations previously demonstrated to show antiproliferative effects on mouse 
keratinocytes (10-9Μ - 10-6Μ),9 and subjected them to proliferation assay. Consistent with 
previous similar findings,9 only the immortalized C5N cells were growth-inhibited by 
dexamethasone, in a concentration-dependent manner. P6, B9, A5 and CarB cells continued 
to proliferate despite dexamethasone presence (Fig. 1a). Dexamethasone induced no effect 
in P6, B9, A5 and CarB cells, neither proliferative nor antiproliferative. On the other hand, 
each tested dexamethasone concentration reduced proliferation rate of the GC-responsive 
C5N cells in a time-dependent manner (Fig. 1b). ANOVA utilising Dunetts’ T3 post-hoc 
analysis demonstrated that C5N cells showed significant sensitivity to dexamethasone. In 
particular, at 72 hours, significant loss of survival was observed at 10-8, 10-7, and 10-6  
concentrations (p=0.014, p=0.002, p<0.001 respectively). On the contrary, no significant 
difference observed between the untreated and treated P6 cells at any dexamethasone 
concentration (Fig. 1b). Therefore, the cells of our system were categorized to GC-sensitive 
(C5N; susceptible to growth inhibition by GCs) and to GC-resistant (P6, B9, A5 and CarB; no 
response to GCs, neither proliferative nor antiproliferative).    
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GR expression and localization status in the multistage mouse skin carcinogenesis 
model 
Then, we monitored GR expression and localization in each cell line of our model. First, 
western blot revealed an elevation of total GR levels towards more aggressive cancer stages. 
Nuclear GR levels gradually increase, showing an abrupt increase during B9-to-A5 transition, 
whereas there is a reduction of cytoplasmic GR protein levels from B9 to A5 cells, 
documenting a switch of the cytoplasmic-to-nuclear ratio upon B9/A5 transition, which is 
independent from GC presence (Fig. 2b). This tendency of GR to translocate to the nucleus 
during squamous-to-spindle transition was further confirmed by immunocytochemistry, which 
revealed cytoplasmic GR localization in C5N, P6 and B9 cells, and mixed cytoplasmic-
nuclear localization in A5 and CarB cells (Fig. 2c). The GR nucleocytoplasmic translocation at 
the squamous-to-spindle threshold was additionally confirmed by immunofluorescence in B9 
and A5 cells, which revealed a clear cytoplasmic signal in B9 cells, but an intense nuclear 
staining in A5 cells (Fig. 2d). To the best of our knowledge, this mixed cytoplasmic and 
nuclear GR localization in aggressive stages has never been reported before. To exclude the 
possibility that this observation is a cell-line artefact, we confirmed it immunohistochemically 
in vivo, on sections from skin tumors induced in mice following a chemical carcinogenesis 
protocol. Indeed, on tumors of the same animal, papilloma stage presents mainly cytoplasmic 
GR localization whereas in the corresponding squamous stage GR localization is more 
intense and gets even more intense in the spindle stage-tumors (Fig. 2e).  
 
GR is GRE-binding competent but transactivation-incompetent in the GC-resistant 
cells of the mouse skin carcinogenesis model 
Then, we tested whether GC-unresponsiveness of P6, B9, A5 and CarB cells is associated 
with reduced DNA binding of GR to GRE-containing targets. EMSAs were performed using 
nuclear cell extracts of C5N, P6, B9, A5 and CarB incubated with a 32P-labelled double 
stranded oligonucleotide that contains a GRE binding site from the human metallothionin II 
promoter (hMTII-GRE). The binding of GR to GREs remains ligand-dependent only in the in 
the GC-sensitive C5N cell line (Fig. 3a), in contrast to the GC-resistant P6, B9, A5 and CarB 
cells, in which GR has acquired the ability to bind to GREs in the absence of dexamethasone 
(Fig. 3b). Additionally, the pattern of GR DNA binding along the five cell lines is consistent 
with their nuclear GR expression profile. This evidence indicates that the ability of GR to bind 
to GRE-containing targets through its DNA binding domain remains intact and proportional to 
the nuclear GR levels (Fig. 3b). Therefore, we plausibly hypothesized that although GR binds 
to target GREs in a ligand-independent manner in the P6, B9, A5 and CarB cells, it might be 
incapable of transactivating its targets, thus providing a reason for their GC-resistance. To 
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this end, we then tested whether unresponsiveness of GC-resistant cells to GCs might be 
associated with inability of GRE-bound GR to transactivate crucial antiproliferative targets. 
We used luciferase assays to monitor the ability of endogenous GR to activate the 
glucocorticoid-responsive enhancer of β-globin in the presence of dexamethasone in all 
mouse cell lines (Fig. 3c). Significant luciferase activity was observed only in the GC-sensitive 
C5N cells upon GC treatment. In parallel, using Q-PCR, we estimated the endogenous 
expression of the characteristic GC-responsive antiproliferative direct GR targets p57KIP2 31 
and GILZ (Glucocorticoid-induced leucine zipper)32 in dexamethasone-treated versus 
dexamethasone-untreated cells. In agreement with the luciferase assay findings, both targets 
were significantly induced (t-test, p<0.05) in the GC-responsive C5N cells upon 
dexamethasone treatment, whereas the corresponding levels were not upregulated after 
addition of dexamethasone in all GC-resistant cells (Fig. 3d and 3e). However, sequencing 
analysis revealed that this impairment is not attributed to direct mutations in the domains of 
the GR gene that are responsible for the GR transactivation function (Supplementary Material 
1). 
 
N-bromotaurine induces antiproliferative effects in GC-resistant cancer cell lines  
Then, we checked whether BrTaur restores antiproliferative response in our model system. 
To this end, we treated cells with 25μM, 75μM, 125μM and 250μM BrTaur and subjected 
them to proliferation assays. This range is consistent with the therapeutic concentrations 
currently used, in the investigational clinical setting against inflammatory conditions and 
microbial infections.13,15  BrTaur exerted a potent, dose-dependent antiproliferative effect in 
the GC-sensitive C5N and the GC-resistant P6, B9, A5 and CarB cells, which is evidenced 
from 125μM (Fig. 4a). The maternal substance taurine, from which BrTaur is produced upon 
reduction with HOBr, has been previously reported to exert anticancer properties33,34 . 
Therefore, we treated cell lines with the concentration range of unbrominated taurine that 
corresponded to the tested concentration range of its brominated derivatives23. Taurine 
treatment did not affect mouse skin cancer cell proliferation in a significant, potent and 
consistent manner (Fig. 4b), implying that bromination of the taurine is the crucial factor for 
the consistent antiproliferative effect on cells. ANOVA utilising Dunetts’ T3 post-hoc analysis 
demonstrated that P6 cells showed significant sensitivity at concentrations over 75μM 
bromotaurine. A5, B9 and CarB cell lines demonstrated sensitivity at concentrations over 
125μM bromotaurine. The GC-responsive C5N cells are the least sensitive to bromotaurine,. 
The BrTaur antiproliferative effect was reproduced in GC-resistant human cancer cells of 
epithelial origin, i.e. the prostate cancer cell line PC3 (Fig. 4c) and the breast cancer cell line 
MDA-MB-231 (Fig. 4d)35,36 in the tested concentration range.  
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N-bromotaurine inhibits cell cycle progressionin GC-resistant cells   
Unlike dexamethasone (Fig. 5a), BrTaur induced antiproliferative effects on the GC-resistant, 
aggressive CarB cells in a concentration- and time- dependent manner (Fig. 5b). GCs inhibit 
cancer cell growth, at least in part, by blocking cell cycle at the G0/G1 phase. This ability of 
GCs to induce G1-arrest is often compromised in GC-resistant cancer cells.30 In this context, 
we examined whether BrTaur bypasses lack of antiproliferative response in the GC-resistant 
cells by restoring G1-arrest. Using FACS analysis, we estimated the effect of three different 
BrTaur concentrations (125μM, 250μM and 500μM) on the G0/G1, S and G2/M phases, using 
the most aggressive GC-resistant cell line of our model system, i.e. CarB. Dexamethasone 
was used as the comparator substance and untreated cells were used as negative control. 
Dexamethasone was unable to induce G1-arrest, thus having an effect on cell cycle 
progression identical to the one observed for the GC-untreated cells. On the contrary, BrTaur 
in the concentrations of 125μM and 250μM enhanced the percentage of cells in G1 phase, 
thus simulating the effect of GCs on cell cycle. Interestingly, in the high, yet clinically 
physiological, concentration of 500μM, BrTaur potently affected both G1 and G2 phases, 
demonstrating a broader ability to target cell cycle. Its effect on the S phase is moderate and 
seems to be dose-dependent (Fig. 5c). The experiment was performed in triplicates and 
presented a p value <0.05 (t-test).  
 
Ciplatin efficacy on GC-resistant cells is potentiated by N-bromotaurine:  the earlier the 
initiation of N-bromotaurine co-administration, the more enhanced the synergistic 
effect 
In clinical cancer therapeutics, GCs are routinely co-administered with cisplatin, either as 
adjuvant agents or to mitigate cisplatin adverse events. Therefore, for a substance to 
clinically qualify as a GC-substitute in the context of cancer, it should be able to enhance 
cisplatin’s effects on tumor growth. To test if this applies for N-bromotaurine, we treated the 
GC-resistant aggressive spindle CarB cells of the mouse carcinogenesis model with a 
combination regimen of cisplatin plus N-bromotaurine. Three treatment schemes were used: 
a) pre-treatment, i.e. BrTaur 0-48h, followed by cisplatin 24-48h; b) concurrent treatment, i.e. 
BrTaur plus cisplatin, 0-48h; c) post-treatment, i.e. cisplatin 0-24h, followed by BrTaur 24-
48h. Since the qualitative effect of BrTaur on cell cycle progression is dose-dependent for the 
higher 250μΜ (affects G1) and 500μΜ (affects both G1 and G2) concentrations (Fig. 5c), we 
tested both concentrations in the BrTaur-containing combination regimens. Each scheme was 
compared versus its corresponding comparator combination regimen of cisplatin plus 10-7M 
dexamethasone. Strikingly, both BrTaur concentrations in all-three schemes synergized 
efficiently with 2.9μg/mL cisplatin (a value corresponding to the cisplatin concentration 
efficient to kill 27% of CarB cells; CarB IC50:3.7μg/mL) (Supplementary Material 2), 
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demonstrating significant superiority versus the corresponding comparator cisplatin plus 
dexamethasone regimens (Fig. 5d-f). ANOVA applying Dunnet’s T3 post-hoc test showed 
that both BrTaur concentrations were efficient in all-three schemes (p≤0.001). The most 
potent synergistic effect was observed for the pre-treatment scheme, where both doses of 
250μM and 500μM achieved similar efficacy. The synergistic effect was dose-dependent in 
concurrent treatment and post-treatment protocols. On the contrary, dexamethasone addition 
did not result to significant increase of the anti-proliferative effect of the regimen, either 
before, concurrently or following cisplatin treatment. Overall, the earlier the BrTaur co-
administration started, the better its synergistic effect with cisplatin on CarB cell growth 
inhibition. Among the three treatment schemes, the inhibitory effect of cisplatin on cell growth 
was less potent in the post-treatment protocol; however higher doses of BrTaur were able to 
compensate for the delay of initiation of BrTaur co-administration (Fig 5f, fourth column).  
 
DISCUSSION 
Analogous to the microbes that develop a plethora of strategies to eventually become 
resistant to antibiotics, cancer cells invent several strategies to impair GR and overcome GC-
sensitivity.2 In several cases, a singleton cause of impairment cannot be identified, because 
GC-resistance is rather multifactorial and attributed to orchestrated inactivation of several 
GR-controlled pathways.2,7,8 In this context, trying to identify impaired GR pathway(s) 
underlying GC-resistance and develop de novo a druggable molecule to restore 
responsiveness poses as a herculean task. A different approach to bypass GC-
unresponsiveness of cancer cells would be to reposition alternatives from the pharmaceutical 
arsenal that are either approved or in late-stages of clinical trials for other GC-refractory 
inflammatory conditions. Given the emerging commonalities between inflammation and 
cancer, those alternatives might pose as latent substitutes of GCs’ antiproliferative effect, 
awaiting in a “diamond-in-a-rough” state to be revisited in the context of cancer. This might 
decrease the pressure for natural selection of cancer cells that overcome the GC 
antiproliferative effects by deactivating their GR receptor and/or the GR-mediated pathways, 
the same way that prudent use of antibiotics or use of interchangeable antibiotics prevents 
the development of antibiotic-resistant microbe strains. Using GC-substitutes before ending-
up prescribing GCs would also enable clinical oncologists to reserve the GC-based 
therapeutic options as a last-resort for aggressive tumors, without risking a possible induction 
of GC-resistance in earlier tumor stages.    
To test this hypothesis we considered the mouse skin carcinogenesis system as our 
basal screening tool kit. Overall, the characteristics of our study system in terms of GC-
sensitivity/GC-resistance and the underlying GR status are summarized in Table II. The 
model includes a GC-sensitive cell line C5N which retains a functional GR and can be used 
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as the positive, comparative screening control cell line of the panel. The rest of the cell lines 
represent GC-resistant papillomas, squamous and spindle cells. In terms of localization, we 
additionally observed a GR accumulation in the nucleus during transition from squamous-to-
spindle stages, resulting to a mixed cytoplasmic and nuclear signal in spindle cells. This 
unexpected and previously unreported finding, which was reconfirmed in in vivo mouse 
spindle skin cancer tumors, indicates the possible existence of an heterogenous population of 
GR isoforms and/or variants, some of which may have dominant negative function to the 
typical full-length isoforms. From the pathology point of view, this means that GR nuclear 
localization may not be a positive clinical indication for GC-responsiveness, as originally had 
been suggested 37, especially given the fact that several dominant negative GR isoforms or 
splice variants that antagonize functional, full-length GR, and cause GC-unresponsiveness 
are also localized in the nucleus.1,2These issues will be clarified in future studies. 
BrTaur, our first study case to be checked with our system, presents overlapping 
characteristics with GCs and is topically used in skin inflammatory conditions, such as acne 
vulgaris, instead of steroids 13. It is well-tolerated and presents insignificant side-effects.13,15 
BrTaur surrogated for the antiproliferative effect on GC-sensitive and GC-resistant cells, thus 
providing the first evidence for its potential to be used interchangeably to GCs in the context 
of cancer, in the same concept they are currently clinically used interchangeably to GCs in 
the context of chronic inflammations and microbial infections. The fact that BrTaur efficiently 
synergizes with cisplatin to inhibit growth of GC-resistant cells further highlights its GC-
mimicking therapeutic effect. The antiproliferative effect is strongly linked to the bromine 
moiety of the bromotaurine molecule and is mediated by inhibition of cell cycle in GC-
resistant cells. The ability of BrTaur to produce a more consistent anticancer effect than 
taurine could be explained by the fact that the former is the oxidizingrapidly drastic form, 
while the latter is the maternal, reservoir substance, considered as a pro-drug. In detail, 
taurine is retained in several tissues, primarily in liver, and is recruited in tissues undergoing 
oxidative stress by topically-produced HOCl and HOBr to finally be oxidizedreduced to its 
effectivedrastic taurine haloamine derivatives. These scavenge the toxicity of the excess 
HOCl and HOBr and pick up the torch of immunologic responses at the lesion sites, 
preventing inflammation and exerting anti-microbial and oxidizingantioxidant-like properties13. 
In this respect, the inconsistent efficacy of taurine versus N-bromotaurine on the different cell 
lines of the mouse carcinogenesis system may be due to fluctuated micro-concentrations of 
HOBr in each different cell line milieu, thus resulting to corresponding fluctuations in the 
concentration of the active BrTaur finally being formed.  
It should be noted that overproliferation in our system, as in actual tumors, is 
associated with deregulation of several main pathways in addition to GR transactivation 
impairment.19 These pathways, such as the ERα and AP-1 oncogenic pathways, crosstalk 
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with GR since they are antagonized by its transrepression mode of action. Their progressive 
overactivation towards the aggressive stages in our system22,26,38 implies a dysfunctional GR 
transrepression mode additionally to the demonstrated impairment of GR transactivation 
mode. Furthermore, the mixed cytoplasmic and nuclear signal detected in aggressive stages 
of skin cancer indicates the possible existence of a heterogeneous population of GR isoforms 
and/or variants, some of which may have dominant negative function to the typical full-length 
isoforms. This could be an additional reason for GR’s inability to transactivate its targets and, 
thus, to subsequently mediate the antiproliferative effects of GCs in GC-resistant cells. This 
would mean that multiple factors causing GC-resistance are possibly accumulating towards 
the most aggressive stages. Therefore, our system must not be seen as a model dedicated to 
the study of a single GC-resistance cause. Rather, it should be cautiously used as a tool kit 
for performing preliminary screenings in order to discriminate the alternative agents with no 
antiproliferative action from the ones with the potential to restore antiproliferative response in 
GC-resistant cells.  
Notably, although skin cancers are primarily associated with impairment of the GR/GC 
axis, they are not treated with GCs. Thus our model is not proposed as a means to spot GC-
substitutes against this cancer type. However, it is the demonstrated ability of this skin 
cancer-based artificial model to produce results that are extrapolated to several other types of 
epithelial cancers21, including the ones that are commonly treated with GCs, that gives this 
model an added value as an emerging generalized screening tool kit for identifying GC-
substitutes. Using this basal screening tool, substances that are suspected, based on medical 
experience in the clinic, to have overlapping profiles with GCs could be confirmed as GC-
substitutes before being repurposed for the management of cancer patients. Based on this 
screening tool, investigational N-bromotaurine was shown to act as a GC-substitute, while its 
effects where reproduced in cancer types that are commonly treated with GCs, such as the 
GC-resistant human breast and prostate cancer cell lines. Further confirmation of this anti-
tumor effect in experimental animals in future studies could accelerate subsequent 
repositioning of BrTaur for the management of clinical cancer patients. 
The point our approach highlights is that already-in-clinical-use compounds, able to 
consistently induce an antiproliferative phenotype in GC-resistant cells, even via molecular 
circuits which are currently as unknown to molecular biologists, as are unfamiliar to the GC-
resistant cancer cells themselves, warrant to be unveiled and considered as possible GC-
substitute therapeutic solutions. Analogous with what happens with newer generation 
antibiotics that catch the microbes unawares, the success of such compounds to startle 
cancer cells towards an antiproliferative direction may rely to their possible ability to act 
through pathways that the cancer cells have never been called to deactivate before in order 
to become aggressive. Such GC-substitutes may have the clinical potential to prolong 
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disease free-survival, reduce tumor size, delay progression, mitigate side-effects and improve 
quality of life, in combination with well-established drugs, thus complying to the FDA’s 
established guidelines on cancer clinical trial end-points. 
(http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf).  
Last but not least, burning issues regarding BrTaur mechanism of action are awaiting 
to be thoroughly addressed in future studies. Potential ways for its systemic administration in 
the context of cancer therapeutics should also be explored. Anti-inflammatory effects of 
BrTaur are mediated by modification of the IkappaBalpha, an NF-kappaB inhibitor39. This 
interaction could also underlie BrTaur antiproliferative effects on GC-resistant cells, given that 
NF-kappaB stands in the cross-roads between inflammation and cancer40 and is a crucial 
effector of GR-mediated tumor-suppressor effects2. Given the commonalities shared between 
anti-inflammatory and anti-cancer pathways, BrTaur may, at least in part, exert its anti-cancer 
action, in addition to its well-known anti-inflammatory properties13 by targeting common 
networks underlying both pathological entities17,18. Comprehensive, high-throughput analyses 
of the molecular and cellular changes and the transcriptional programs alterations triggered 
upon BrTaur treatment using state-of-the-art, multiomics approaches are anticipated to shed 
more light on this issue in the future. The full range of BrTaur functions might extend beyond 
interfering with GR-mediated pathways, and is currently under investigation. The role of 
BrTaur in cancer emerges as a subject of fruitful research and poses as a mysterious “black 
box”, the decoding of which might pave the way for next generation therapeutics. 
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FIGURE LEGENDS 
 
Figure 1: Estimation of responsiveness of cell lines of the mouse skin carcinogenesis model 
to GCs (dexamethasone) by crystal violet assays. (a) In the representative time point of 48h, 
the percentage number of cells drastically decreases proportional to dexamethasone 
concentration in comparison with the untreated cells in the C5N cell line (expressed as ratio 
to untreated cells). In contrast, there is no change in cell numbers of dexamethasone-treated 
P6, B9, A5 and CarB cells compared to their corresponding untreated controls, in any of the 
concentrations tested. (b) The profile of the antiproliferative action of GCs on the GC-
sensitive C5N cells over time, for each of the tested dexamethasone concentrations in 
comparison to a selected GC-resistant cell line P6. The experiments were performed in 
triplicates. 
   
Figure 2: GR is translocated in nucleus during transition from squamous to spindle stage of 
skin carcinogenesis. (a) GR protein expression levels of total (tGR), cytoplasmic (cGR) and 
nuclear (nGR) extracts of the mouse skin carcinogenesis model. (b) Quantification of 
Western blot results indicates a switch in the cytoplasmic-to-nuclear GR ratio (cGR-to-nGR) 
during transition from squamous to spindle stage. (c) Immunocytochemistry analysis of the 
panel of mouse skin carcinogenesis model with anti-GR antibody revealed cytoplasmic 
staining in C5N, P6 and B9 cells, and mixed cytoplasmic and nuclear staining in A5 and CarB 
cells. The black arrows indicate GR-stained nuclei. These immunocytochemical patterns were 
rather uniform in the above mentioned cell lines. (d) The immunofluorescence GR signal is 
cytoplasmic in the squamous B9 cells, but nuclear in the spindle A5 cells. (e) 
Immunohistochemistry using anti-GR antibody in paraffin-embedded tissues isolated from the 
papilloma, squamous and spindle stage of the same chemically-induced tumor in one mouse 
revealed higher number of GR-stained nuclei in spindle cells in comparison with the 
corresponding papilloma and squamous stage. Each figure represents a 200x magnitude, 
whereas the upper-right boxes in each figure represent a 400x magnitude. The black boxes 
represent the magnified area. The black arrows indicate GR-stained nuclei.  
 
Figure 3: GR is DNA binding-competent but transactivation-incompetent in GC-resistant cell 
lines of the mouse skin carcinogenesis model. (a) Electrophoretic mobility shift assay in the 
GC-responsive C5N revealed binding activity of GR to glucocorticoid responsive elements 
(GRE) only upon dexamethasone (C5N+dex) treatment. (b) EMSA assay for GR using 
nuclear extracts demonstrated binding activity of GR to glucocorticoid responsive elements 
(GRE) of the GC-unresponsive P6, B9, A5 and CarB cells in the absence of dexamethasone 
signal. DNA binding increases directly proportional to the demonstrated nuclear GR protein 
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levels towards more aggressive cell lines. Specificity of the EMSA reaction is confirmed by 
supershift reactions in A5 (lane 6) cells using anti-GR antibody. (c)  Luciferase assays in the 
GC-sensitive and the GC-resistant cells of the mouse skin carcinogenesis model co-
transfected with the 17m-GRE-G-Luc, in dexamethasone absence (-dex) or presence (+dex). 
Luciferase expression is significantly induced (One asterisk (*) denotes p <0.05) only in the 
GC-sensitive C5N cells upon dexamethasone treatment. Error bars represent the standard 
error of the mean. Two-tailed p values are are derived from independent t-tests. Three 
biological replicates were available for each experiment. (d) Box plots demonstrating the 
transcription induction of GILZ under dexamethasone treatment in Q-PCR estimation of GILZ 
levels in the GC-sensitive and the GC-resistant cell lines before (-dex) and after (+dex) 
dexamethasone treatment, estimated by qPCR. The relative quantification (RQ) values in 
log10 are shown. For each cell line, the untreated control was used as calibrator. The 
housekeeping gene beta-2 microglobulin was used as an internal control of mRNA Q-PCR 
expression. The experiments were performed in triplicates. (e) Same as 3d, for p57KIP2 mRNA 
levels.  In both genes, significant induction is only observed in C5N cells (indicated by star). 
RQ: relative quantification value. 
 
 
Figure 4: Estimation of the antiproliferative response of the GC-sensitive and the GC-
resistant cell lines to N-bromotaurine by proliferation assays. (a) In the representative time 
point of 48h, the percentage number of cells drastically decreases in comparison with the 
corresponding untreated control cells for all cell lines of the study model (expressed as ratio 
to untreated cells). (b) Comparative treatment of the cells with the maternal substance taurine 
did not affect mouse skin cancer cell proliferation in a significant and consistent manner, 
implying that bromination of the taurine is the crucial factor for the consistent antiproliferative 
effect on cells. (c) The profile of the antiproliferative action of N-bromotaurine on the GC-
resistant GC-resistant prostate cancer PC3. (d) Same as 4c. for the human GC-resistant 
prostate cancer MDA-MB-231. The experiments were performed in triplicates. 
 
Figure 5: Comparison of the antiproliferative response of the aggressive GC-resistant cells to 
GCs versus N-bromotaurine. (a) proliferation assays on CarB cells treated with 
dexamethasone reveal lack of significant antiproliferative response of CarB upon addition of 
GCs over time, as evidenced by the OD measurements. (b) In contrast, proliferation assays 
on CarB cells treated with N-bromotaurine instead of dexamethasone reveal restoration of 
antiproliferative response of CarB cells by N-bromotaurine over time. The restoration of 
antiproliferative response is statistically significantpotent in the 250μM concentration, after 48 
and 72 hours of N-bromotaurine treatment. Three independent experiments were performed, 
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each in triplicate. Mean values were significantly different from those of the untreated controls 
in the N-bromotaurine-treated cells, but not in the dexamethasone-treated cells. The 
means+SEM values are shown in the graphs.. (c) FACS analysis of N-bromotaurine-treated 
CarB cells (CarB + BrTaur) compared with dexamethasone-treated CarB cells (CarB + dex) 
and untreated CarB cells (CarB). BrTaur, at concentrations of 125μΜ and 250μΜ,  increased 
the number of cells in G0/G1 phase; whereas at the high concentration of 500μΜ, BrTaur 
drastically decreased both G0/G1 and G2/M phases. Dexamethasone, at 10-7M concentration 
failed to significantly affect the number of cells in G1/G0 phase. Corresponding summary 
graphs for each phase of the cell cycle (means±SEM from 3 independent FACS analyses 
measurements) derived by comparison of untreated CarB cells each of the dexamethasone-
treated, 125μΜ BrTaur-treated, 250μΜ BrTaur-treated and 500μΜ BrTaur-treated CarB cells, 
using t-test. (d-f) 250μΜ BrTaur-treated and 500μΜ BrTaur-treated CarB cells synergized 
efficiently with 2.9 cisplatin (cis) after 48hours of BrTaur plus cisplatin combination therapy as 
(d) pre-treament (BrTaur + cis), (e) concurrent treatment (cis/BrTaur) or (f) post-treatment (cis 
+ BrTaur) , t-test, p-value <0.05. Results are flagged with no asterisk when p-value is more 
than 0.05, and with twoan asterisks when the p-value is less than 0.0015. (See text for details 
on treatment schemes of 5d-f).  
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ABSTRACT 
Glucocorticoids (GCs) are frequently used in anticancer combination regimens; however, 
their continuous use adds selective pressure on cancer cells to develop GC-resistance via 
impairment of the glucocorticoid receptor (GR), therefore creating a need for GC-alternatives. 
Based on the drug repurposing approach and the commonalities between inflammation and 
neoplasia, drugs that are either in late-stage clinical trials and/or already marketed for GC-
refractory inflammatory diseases, could be evaluated as GC-substitutes in the context of 
cancer. Advantageously, unlike new molecular entities currently being de novo developed to 
restore GC-responsiveness of cancer cells, such drugs have documented safety and efficacy 
profile, which overall simplifies their introduction in clinical cancer trials. In this study, we 
estimated the potential of a well-established, multistage, cell line-based, mouse skin 
carcinogenesis model to be exploited as an initial screening tool for unveiling covert GC-
substitutes. First, we categorized the cell lines of this model to GC-sensitive and GC-
resistant, in correlation with their corresponding GR status, localization and functionality. We 
found that GC-resistance starts in papilloma stages, due to a dysfunctional GR, which is 
overexpressed, DNA binding-competent, but transactivation-incompetent in papilloma, 
squamous and spindle stages of the model. Then, aided by this tool, we evaluated the ability 
of N-bromotaurine, a naturally-occurring, small-molecule, NSAID which is under consideration 
for use interchangeably/in replacement to GCs in skin inflammations, to restore 
antiproliferative response of GC-resistant cancer cells. Unlike GCs, N-bromotaurine inhibited 
cell-cycle progression in GC-resistant cancer cells and efficiently synergized with cisplatin, 
thus indicating a potential to be exploited instead of GCs against cancer.  
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INTRODUCTION 
 Glucocorticoids (GCs) are steroid hormones which inhibit tumor cell proliferation, 
mitigate chemotherapy side effects and enhance efficiency of anticancer agents1,2. They are 
frequently included in combination anticancer therapies, either as palliative agents against 
chemotherapy-induced-nausea-and-vomiting or as antiproliferative agents. Their effects are 
mediated by the glucocorticoid receptor (GR). GC binds to GR which, following dissociation 
from a cytoplasmic chaperone/co-chaperone complex, translocates to the nucleus, 
homodimerizes and regulates gene expression. GR transactivates or transrepresses genes 
by direct binding to GREs (glucocorticoid responsive elements), by tethering itself to other 
transcription factors apart from DNA binding, or in a composite manner by both direct GRE 
binding and interactions with transcription factors bound to neighboring sites (reviewed by 
Ramamoorthy et al2). Thus, a functional GR elicits tumor-suppressive events in a pleiotropic 
manner, through a plethora of mechanisms and crucial pathways.3-5 
Theoretically, the clinical benefits demonstrated by the long-term experience on GCs, 
combined with the tumor-suppressive nature of GR, offer a strong alibi for their routine use in 
cancer therapeutics (e.g. prostate cancer, breast cancer, leukemia), as evidenced by the 
increasing number of GC-containing combination regimens, both established and 
investigational. Nevertheless, GC cotreatment often induces resistance towards cancer 
therapy1,6 thus raising concerns regarding the tendency of GC-sensitive cancer cells to 
develop resistance upon frequent GC use. Mechanistically, this tendency is attributed to the 
pleiotropic nature of GR per se. GR’s pleiotropy becomes a double-edged sword, since 
cancer cells have, at their disposal, as many potentials to overcome GR’s antiproliferative 
barrier and achieve GC-resistance, as is the plethora of underlying GR-mediated 
antiproliferative pathways they can defuse one way or another. For neutralizing GR 
antiproliferative effects, cancer cells exploit several strategies, which in several cases 
simultaneously co-exist in a cancer cell (e.g. reduced GR expression, reduced DNA binding 
ability, GR mutations and polymorphisms, co-expression of dominant negative GR isoforms, 
impairment of transrepression mode et.c.).2,7,8 GC-unresponsiveness by GR impairment may 
start as early as the benign stages, highlighting that inactivation of GC/GR axis is a selective 
advantage in order for a cancer cell to surpass the antiproliferative break and continue its 
tumorigenic march towards aggressive stages.9 
This overall necessitates alternatives restoring and/or surrogating for GCs’ 
antiproliferative effects.2,10 To this end, innovative synthetic molecules are being developed 
by academia, aiming to re-activate GR-mediated antiproliferative pathways and restore GC-
responsiveness of cancer cells10. If they successfully pass clinical trials, they will eventually 
find their way to the bedside. But this established bench-to-bedside pipeline is not an one-
way street. The recently framed concept of drug repurposing suggests evaluating suitability of 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
known drugs for use in new indications11. Implementing this concept in the issue of GC-
resistance, we postulate that drugs which are already in late stages of clinical trials or 
approved for indications other than cancer may be latent GC-substitutes, able to imitate 
aspects of the GC therapeutic profile. These hypothetical latent GC-substitutes might be 
competent to either restore the antiproliferative phenotypes in GC-resistant cells; or to be 
used interchangeably to GCs, in order to reduce the selective pressure exerted by continuous 
use of GCs on GC-sensitive cells, thus preventing/delaying their clonal expansion to GR-
impaired and, hence, GC-resistant cells. A clinical advantage of the proposed approach is 
that these candidate substances are actually closer to the bedside than they are to the bench, 
since they have a more characterized efficacy and safety profile, in terms of their 
documentation for other therapeutic indications. This is translated to both faster filing and 
regulatory approval procedures and to reduced financial costs to develop these substances 
as anticancer agents, compared to starting the anticancer drug research-and-development 
workflow from scratch, i.e. by developing New Molecular Entities (NMAs, defined by FDA as 
experimental substances without precedent among regulated and approved drug products).11 
Except for anticancer agents, GCs are also common anti-inflammatory agents. In fact, 
their use against inflammations historically preceded their use against neoplasias. GC-
resistance is a frequent problem in inflammations as well, and drugs are being developed in 
replacement of GC-containing anti-inflammatory regimens.12 Emerging GC-substitutes that 
are currently in the investigational clinical setting for inflammation management include, but 
are not limited to, the NSAID (Non-Steroid Anti-Inflammatory Drug) taurine haloamine 
derivatives, mainly N-bromotaurine (BrTaur) and N-chlorotaurine (ClTaur). These are 
generated by eosinophils and neutrophils at a site of inflammation and exert potent anti-
inflammatory properties. Other common features shared with GCs is their naturally-occurring 
and small-molecule nature and their immunomodulatory and antimicrobial properties13. 
Another common characteristic is the potential to ameliorate chemotherapy-induced nausea 
and vomiting, since their maternal substance, i.e. the non-essential aminoacid taurine, which 
is orally administered as a pro-drug in order to be converted to the haloamine derivative at 
the site of inflammation, was recently proven clinically capable of such an effect in leukemic 
patients.14 Advantageously, taurine haloamines have shown good efficacy, tolerance and 
insignificant toxic effects upon topical use on clinical patients who are refractory to 
conventional GC-based anti-inflammatory therapies13,1516. Based on the association between 
chronic inflammatory diseases and neoplasias,17,18 we postulated that a drug which exerts 
overlapping features and common therapeutic indications with GCs and is able to surrogate 
for GCs in GC-resistant inflammations may be able to surrogate for the GCs’ antiproliferative 
function in GC-resistant cancer cells as well.  
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As a springboard for testing this hypothesis, we took advantage of our long-term 
experience on a well-established mouse model of skin carcinogenesis.19 This comprises of a 
series of cell lines which represent different stages of mouse skin tumor progression and are 
categorized on the basis of increasing aggressiveness to immortalized keratinocytes (C5N), 
benign papillomas (P6), malignant squamous carcinomas (B9), and highly invasive spindle 
cells (A5, CarB).19 The B9:A5 pair represents the clonal expansion from squamous to spindle 
stages. The model has been developed in Dr. A. Balmain’s lab and has been thoroughly 
reviewed18 and described previously.20 Briefly, in order to obtain these cell lines, each of 
which represent the initiation, promotion or progression stages of skin carcinogenesis, a 
chemical carcinogenesis protocol on mice was applied. The normal epidermis of mice or 
normal epithelial mouse cells were treated with a single dose of the polycyclic aromatic 
hydrocarbon 7,12 dimethylbenz[a]anthracene (DMBA), followed by weekly applications of the 
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). This led to the development of 
numerous benign papillomas, some of which progressed to malignant squamous cell 
carcinomas several weeks after the first exposure to carcinogens and cell lines were 
produced from these tumors. Overall, this model poses the following advantages: a) it is 
multistage, meaning that it simulates the step-wise manner by which a tumor initiates, 
promotes and progresses, b) it is coherent, since cell lines have been derived in a consistent 
manner following a meticulous chemical carcinogenesis protocol, c) although skin-tissue 
based, it further applies to almost all epithelial cancers.21 Furthermore, the fact that the model 
is skin tissue-based facilitates our analysis, because skin cancer is a traditional field where 
the mechanisms of GR function in correlation to GC-responsiveness have been adequately 
studied.4,5,9 Therefore, although our model has never been characterized before in terms of 
GC-responsiveness, it stood a good chance to faithfully mirror or even complement previous 
robust findings.   
First, we characterized our system in terms of antiproliferative response to GCs. Then, we 
correlated this responsiveness to the underlying GR expression status, localization and 
functionality. Finally, we checked the ability of BrTaur to bypass GC-resistance of cancer cells 
either alone or in combination with cisplatin.  
 
 
MATERIALS AND METHODS 
Cells and culture conditions  
Mouse cell lines of the mouse skin carcinogenesis model have been produced and obtained 
by Dr. Allan Balmain. All human cell lines used were obtained by American Type Culture 
Collection (ATCC). Cells were cultured as previously described.22 The preparation23 and use 
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of BrTaur is covered by licensing agreement. The in-house formulation was donated by 
NASCO AD Biotechnology Laboratory for preclinical research purposes.  
 
Proliferation assays 
Collectively, 2250 cells per well were seeded in 96-well plates. After cells were attached, the 
first measurement was taken. This time point is called 0 hours. At this point, 24h after 
seeding, dexamethasone (10-9 – 10-6M, from a stock of 10-3M dexamethasone diluted in 
ethanol), BrTaur (25μM-250μM from a stock of 4mM BrTaur) or taurine (5-50mM from a stock 
of 200mM taurine diluted in water) was added and measurements were taken after 24, 48 
and 72h. For co-treatment experiments, cells were treated with either 10-7M dexamethasone 
or BrTaur (125, 250 or 500μM) 24-hours prior, con-currently with or 24-hours post cisplatin 
treatment. Untreated cells were used as controls. Following treatments, cells were fixed with 
100% methanol and, then, crystal violet solution was added to each well. After a 10-minute 
incubation in room temperature, each well was washed 3 times with 200μL water, and plates 
were incubated on a shaker for 45min. Optical Density (OD) was measured at 595nm using a 
Tecan reader. The data was transferred to Microsoft Excel and analyzed. Background 
absorbance was corrected using triplicate sets of wells containing medium only (no cells) and 
crystal violet reagent as per experimental well. Τhree independent experiments were 
performed and each one of them included a triplicate value set.  
 
RNA extraction, cDNA synthesis and qRT-PCR analysis 
mRNA extraction, cDNA synthesis and quantitative real-time PCR was conducted as 
previously described.24 Primers used appear in Table I.  
 
Preparation of cell lysates and Western blot analysis 
Total, cytoplasmic and nuclear cell lysates were prepared as previously described.25 The 
primary antibody was an in-house anti-GR rabbit polyclonal antibody, clone 2F8, against 
aminoacids 305-427 of the N-terminal domain (kindly provided by Dr. M.N. Alexis), in a 1:500 
dilution. Primary anti-beta-actin antibody in a 1:1000 dilution was used as a loading control. 
The secondary antibody was a mouse anti-rabbit antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) in a 1:1000 dilution. 
 
Two-stage chemical carcinogenesis protocol 
Tumors induced on mouse skin following a chemical carcinogenesis protocol were fixed and 
paraffin-embedded. Slides carrying formalin-fixed paraffin-embedded (FFPE) mouse skin 
papilloma and squamous and spindle tumors were prepared as previously described.22 In 
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vivo experiments were performed in the in-house authorized animal house. Experiments 
complied with the Protocol on the Protection and Welfare of Animals, as obliged by the rules 
of the National Hellenic Research Foundation, the regulations of the National Bioethics 
Committee and the article 3 of the presidential decree 160/1991 (in line with 86/609/EEC 
directive) regarding the welfare of experimental animals. 
 
Immunohistochemical and immunocytochemical staining 
Immunohistochemical staining on FFPE sections was performed as described earlier.26 The 
sections were stained with anti-GR, clone 2F8, in a 1:10 dilution. For the 
immunocytochemistry staining with anti-GR antibody 2F8, we followed the same procedure, 
incubation periods and reagents, by omitting the deparaffinization step.  
 
Immunofluorescence staining 
Cells were grown and fixed on coverslips and where subjected to immunofluorescence 
staining as previously described.27 The slides were incubated with primary antibody anti-GR, 
clone M-20 (Santa Cruz Biotechnology, Santa Cruz, CA) in a 1:50 dilution. The secondary 
antibody was anti-rabbit FITC-conjugated (Jackson Laboratory, Bar Harbor, Maine, USA) 
diluted in 1:100.  
 
Electrophoretic Mobility Shift assay 
Annealed oligonucleotides for the human metallothionin IIA Glucocorticoid Responsive 
Element (5’-TGGTACACTGTGTCCTGAATTCA-3’ and 5’-
TGAATTCAGGACACAGTGTACCA-3’) were end-labeled with γ32P-ATP using T4-
polynucleotide kinase and the reaction products were purified on a 8% polyacrylamide gel. 
DNA binding reactions were performed as previously described.28 For the supershift control 
experiment, the primary polyclonal antibody anti-GR 10-10 (kindly provided by Dr. M. Alexis) 
was used. 
 
Plasmids, transfections and luciferase reporter assay 
A luciferase plasmid carrying GRE sequences (17m-GRE-G-Luc), as well as a control vector 
carrying no GRE binding site (tata-pG13Luc) described previously29 were used for 
transfections. Where indicated, cells were incubated with dexamethasone and transfected 
with by the calcium phosphate method, as described previously7. The luciferase activity was 
measured using a luminometer and was normalized for transfection efficiency with the β-
galactosidase activity.  
 
FACS analysis 
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Cells were harvested, trypsinized and centrifuged at 1,000rpm for 5min, at room temperature. 
The pellet was resuspended in 500μL PBS, fixed with 80% ethanol, vortexed, and stained 
with propidium iodide (50μg/mL), in the presence of 5mmol/L MgCl2 and 10μg/mL RNase A in 
10mmol/L Tris-HCl (pH 7.5). DNA content was analyzed on a FACSCalibur (Becton 
Dickinson) using the Modfit software. 
 
Statistical analysis 
Data are expressed as mean±SD. Each experiment was performed in triplicates. Τhen, the 
triplicate set values of three independent experiments were analyzed. For statistical analyses 
of proliferation assays results, ANOVA utilising Dunetts’ T3 post-hoc analysis  was applied. 
QPCR results were evaluated using Mann-Whitney’s test. Luciferase assays were analyzed 
using independent student’s t-tests. P values of less than 0.05 were considered significant. 
 
 
RESULTS 
The antiproliferative effect of GCs is lost in the promotion and progression stages of 
mouse skin carcinogenesis 
Our first priority was to explore the GC antiproliferative effect on the cell lines of our system. 
GC effect ranges from proliferative in very low concentrations, to cytostatic/antiproliferative in 
more physiological concentrations and cytotoxic/apoptotic in higher concentrations.30 To 
monitor GC effect on our system, we treated cells with a range of dexamethasone 
concentrations previously demonstrated to show antiproliferative effects on mouse 
keratinocytes (10-9Μ - 10-6Μ),9 and subjected them to proliferation assay. Consistent with 
previous similar findings,9 only the immortalized C5N cells were growth-inhibited by 
dexamethasone, in a concentration-dependent manner. P6, B9, A5 and CarB cells continued 
to proliferate despite dexamethasone presence (Fig. 1a). Dexamethasone induced no effect 
in P6, B9, A5 and CarB cells, neither proliferative nor antiproliferative. On the other hand, 
each tested dexamethasone concentration reduced proliferation rate of the GC-responsive 
C5N cells in a time-dependent manner (Fig. 1b). ANOVA utilising Dunetts’ T3 post-hoc 
analysis demonstrated that C5N cells showed significant sensitivity to dexamethasone. In 
particular, at 72 hours, significant loss of survival was observed at 10-8, 10-7, and 10-6  
concentrations (p=0.014, p=0.002, p<0.001 respectively). On the contrary, no significant 
difference observed between the untreated and treated P6 cells at any dexamethasone 
concentration (Fig. 1b). Therefore, the cells of our system were categorized to GC-sensitive 
(C5N; susceptible to growth inhibition by GCs) and to GC-resistant (P6, B9, A5 and CarB; no 
response to GCs, neither proliferative nor antiproliferative).    
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GR expression and localization status in the multistage mouse skin carcinogenesis 
model 
Then, we monitored GR expression and localization in each cell line of our model. First, 
western blot revealed an elevation of total GR levels towards more aggressive cancer stages. 
Nuclear GR levels gradually increase, showing an abrupt increase during B9-to-A5 transition, 
whereas there is a reduction of cytoplasmic GR protein levels from B9 to A5 cells, 
documenting a switch of the cytoplasmic-to-nuclear ratio upon B9/A5 transition, which is 
independent from GC presence (Fig. 2b). This tendency of GR to translocate to the nucleus 
during squamous-to-spindle transition was further confirmed by immunocytochemistry, which 
revealed cytoplasmic GR localization in C5N, P6 and B9 cells, and mixed cytoplasmic-
nuclear localization in A5 and CarB cells (Fig. 2c). The GR nucleocytoplasmic translocation at 
the squamous-to-spindle threshold was additionally confirmed by immunofluorescence in B9 
and A5 cells, which revealed a clear cytoplasmic signal in B9 cells, but an intense nuclear 
staining in A5 cells (Fig. 2d). To the best of our knowledge, this mixed cytoplasmic and 
nuclear GR localization in aggressive stages has never been reported before. To exclude the 
possibility that this observation is a cell-line artefact, we confirmed it immunohistochemically 
in vivo, on sections from skin tumors induced in mice following a chemical carcinogenesis 
protocol. Indeed, on tumors of the same animal, papilloma stage presents mainly cytoplasmic 
GR localization whereas in the corresponding squamous stage GR localization is more 
intense and gets even more intense in the spindle stage-tumors (Fig. 2e).  
 
GR is GRE-binding competent but transactivation-incompetent in the GC-resistant 
cells of the mouse skin carcinogenesis model 
Then, we tested whether GC-unresponsiveness of P6, B9, A5 and CarB cells is associated 
with reduced DNA binding of GR to GRE-containing targets. EMSAs were performed using 
nuclear cell extracts of C5N, P6, B9, A5 and CarB incubated with a 32P-labelled double 
stranded oligonucleotide that contains a GRE binding site from the human metallothionin II 
promoter (hMTII-GRE). The binding of GR to GREs remains ligand-dependent only in the in 
the GC-sensitive C5N cell line (Fig. 3a), in contrast to the GC-resistant P6, B9, A5 and CarB 
cells, in which GR has acquired the ability to bind to GREs in the absence of dexamethasone 
(Fig. 3b). Additionally, the pattern of GR DNA binding along the five cell lines is consistent 
with their nuclear GR expression profile. This evidence indicates that the ability of GR to bind 
to GRE-containing targets through its DNA binding domain remains intact and proportional to 
the nuclear GR levels (Fig. 3b). Therefore, we plausibly hypothesized that although GR binds 
to target GREs in a ligand-independent manner in the P6, B9, A5 and CarB cells, it might be 
incapable of transactivating its targets, thus providing a reason for their GC-resistance. To 
this end, we then tested whether unresponsiveness of GC-resistant cells to GCs might be 
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associated with inability of GRE-bound GR to transactivate crucial antiproliferative targets. 
We used luciferase assays to monitor the ability of endogenous GR to activate the 
glucocorticoid-responsive enhancer of β-globin in the presence of dexamethasone in all 
mouse cell lines (Fig. 3c). Significant luciferase activity was observed only in the GC-sensitive 
C5N cells upon GC treatment. In parallel, using Q-PCR, we estimated the endogenous 
expression of the characteristic GC-responsive antiproliferative direct GR targets p57KIP2 31 
and GILZ (Glucocorticoid-induced leucine zipper)32 in dexamethasone-treated versus 
dexamethasone-untreated cells. In agreement with the luciferase assay findings, both targets 
were significantly induced in the GC-responsive C5N cells upon dexamethasone treatment, 
whereas the corresponding levels were not upregulated after addition of dexamethasone in 
all GC-resistant cells (Fig. 3d and 3e). However, sequencing analysis revealed that this 
impairment is not attributed to direct mutations in the domains of the GR gene that are 
responsible for the GR transactivation function (Supplementary Material 1). 
 
N-bromotaurine induces antiproliferative effects in GC-resistant cancer cell lines  
Then, we checked whether BrTaur restores antiproliferative response in our model system. 
To this end, we treated cells with 25μM, 75μM, 125μM and 250μM BrTaur and subjected 
them to proliferation assays. This range is consistent with the therapeutic concentrations 
currently used, in the investigational clinical setting against inflammatory conditions and 
microbial infections.13,15  BrTaur exerted a potent, dose-dependent antiproliferative effect in 
the GC-sensitive C5N and the GC-resistant P6, B9, A5 and CarB cells, which is evidenced 
from 125μM (Fig. 4a). The maternal substance taurine, from which BrTaur is produced upon 
reduction with HOBr, has been previously reported to exert anticancer properties33,34. 
Therefore, we treated cell lines with the concentration range of unbrominated taurine that 
corresponded to the tested concentration range of its brominated derivatives23. Taurine 
treatment did not affect mouse skin cancer cell proliferation in a significant, potent and 
consistent manner (Fig. 4b), implying that bromination of the taurine is the crucial factor for 
the consistent antiproliferative effect on cells. ANOVA utilising Dunetts’ T3 post-hoc analysis 
demonstrated that P6 cells showed significant sensitivity at concentrations over 75μM 
bromotaurine. A5, B9 and CarB cell lines demonstrated sensitivity at concentrations over 
125μM bromotaurine. The GC-responsive C5N cells are the least sensitive to bromotaurine,. 
The BrTaur antiproliferative effect was reproduced in GC-resistant human cancer cells of 
epithelial origin, i.e. the prostate cancer cell line PC3 (Fig. 4c) and the breast cancer cell line 
MDA-MB-231 (Fig. 4d)35,36 in the tested concentration range.  
  
N-bromotaurine inhibits cell cycle progressionin GC-resistant cells   
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Unlike dexamethasone (Fig. 5a), BrTaur induced antiproliferative effects on the GC-resistant, 
aggressive CarB cells in a concentration- and time- dependent manner (Fig. 5b). GCs inhibit 
cancer cell growth, at least in part, by blocking cell cycle at the G0/G1 phase. This ability of 
GCs to induce G1-arrest is often compromised in GC-resistant cancer cells.30 In this context, 
we examined whether BrTaur bypasses lack of antiproliferative response in the GC-resistant 
cells by restoring G1-arrest. Using FACS analysis, we estimated the effect of three different 
BrTaur concentrations (125μM, 250μM and 500μM) on the G0/G1, S and G2/M phases, using 
the most aggressive GC-resistant cell line of our model system, i.e. CarB. Dexamethasone 
was used as the comparator substance and untreated cells were used as negative control. 
Dexamethasone was unable to induce G1-arrest, thus having an effect on cell cycle 
progression identical to the one observed for the GC-untreated cells. On the contrary, BrTaur 
in the concentrations of 125μM and 250μM enhanced the percentage of cells in G1 phase, 
thus simulating the effect of GCs on cell cycle. Interestingly, in the high, yet clinically 
physiological, concentration of 500μM, BrTaur potently affected both G1 and G2 phases, 
demonstrating a broader ability to target cell cycle. Its effect on the S phase is moderate and 
seems to be dose-dependent (Fig. 5c). The experiment was performed in triplicates and 
presented a p value <0.05 (t-test).  
 
Ciplatin efficacy on GC-resistant cells is potentiated by N-bromotaurine:  the earlier the 
initiation of N-bromotaurine co-administration, the more enhanced the synergistic 
effect 
In clinical cancer therapeutics, GCs are routinely co-administered with cisplatin, either as 
adjuvant agents or to mitigate cisplatin adverse events. Therefore, for a substance to 
clinically qualify as a GC-substitute in the context of cancer, it should be able to enhance 
cisplatin’s effects on tumor growth. To test if this applies for N-bromotaurine, we treated the 
GC-resistant aggressive spindle CarB cells of the mouse carcinogenesis model with a 
combination regimen of cisplatin plus N-bromotaurine. Three treatment schemes were used: 
a) pre-treatment, i.e. BrTaur 0-48h, followed by cisplatin 24-48h; b) concurrent treatment, i.e. 
BrTaur plus cisplatin, 0-48h; c) post-treatment, i.e. cisplatin 0-24h, followed by BrTaur 24-
48h. Since the qualitative effect of BrTaur on cell cycle progression is dose-dependent for the 
higher 250μΜ (affects G1) and 500μΜ (affects both G1 and G2) concentrations (Fig. 5c), we 
tested both concentrations in the BrTaur-containing combination regimens. Each scheme was 
compared versus its corresponding comparator combination regimen of cisplatin plus 10-7M 
dexamethasone. Strikingly, both BrTaur concentrations in all-three schemes synergized 
efficiently with 2.9μg/mL cisplatin (a value corresponding to the cisplatin concentration 
efficient to kill 27% of CarB cells; CarB IC50:3.7μg/mL) (Supplementary Material 2), 
demonstrating significant superiority versus the corresponding comparator cisplatin plus 
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dexamethasone regimens (Fig. 5d-f). ANOVA applying Dunnet’s T3 post-hoc test showed 
that both BrTaur concentrations were efficient in all-three schemes (p≤0.001). The most 
potent synergistic effect was observed for the pre-treatment scheme, where both doses of 
250μM and 500μM achieved similar efficacy. The synergistic effect was dose-dependent in 
concurrent treatment and post-treatment protocols. On the contrary, dexamethasone addition 
did not result to significant increase of the anti-proliferative effect of the regimen, either 
before, concurrently or following cisplatin treatment. Overall, the earlier the BrTaur co-
administration started, the better its synergistic effect with cisplatin on CarB cell growth 
inhibition. Among the three treatment schemes, the inhibitory effect of cisplatin on cell growth 
was less potent in the post-treatment protocol; however higher doses of BrTaur were able to 
compensate for the delay of initiation of BrTaur co-administration (Fig 5f, fourth column).  
 
DISCUSSION 
Analogous to the microbes that develop a plethora of strategies to eventually become 
resistant to antibiotics, cancer cells invent several strategies to impair GR and overcome GC-
sensitivity.2 In several cases, a singleton cause of impairment cannot be identified, because 
GC-resistance is rather multifactorial and attributed to orchestrated inactivation of several 
GR-controlled pathways.2,7,8 In this context, trying to identify impaired GR pathway(s) 
underlying GC-resistance and develop de novo a druggable molecule to restore 
responsiveness poses as a herculean task. A different approach to bypass GC-
unresponsiveness of cancer cells would be to reposition alternatives from the pharmaceutical 
arsenal that are either approved or in late-stages of clinical trials for other GC-refractory 
inflammatory conditions. Given the emerging commonalities between inflammation and 
cancer, those alternatives might pose as latent substitutes of GCs’ antiproliferative effect, 
awaiting in a “diamond-in-a-rough” state to be revisited in the context of cancer. This might 
decrease the pressure for natural selection of cancer cells that overcome the GC 
antiproliferative effects by deactivating their GR receptor and/or the GR-mediated pathways, 
the same way that prudent use of antibiotics or use of interchangeable antibiotics prevents 
the development of antibiotic-resistant microbe strains. Using GC-substitutes before ending-
up prescribing GCs would also enable clinical oncologists to reserve the GC-based 
therapeutic options as a last-resort for aggressive tumors, without risking a possible induction 
of GC-resistance in earlier tumor stages.    
To test this hypothesis we considered the mouse skin carcinogenesis system as our 
basal screening tool kit. Overall, the characteristics of our study system in terms of GC-
sensitivity/GC-resistance and the underlying GR status are summarized in Table II. The 
model includes a GC-sensitive cell line C5N which retains a functional GR and can be used 
as the positive, comparative screening control cell line of the panel. The rest of the cell lines 
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represent GC-resistant papillomas, squamous and spindle cells. In terms of localization, we 
additionally observed a GR accumulation in the nucleus during transition from squamous-to-
spindle stages, resulting to a mixed cytoplasmic and nuclear signal in spindle cells. This 
unexpected and previously unreported finding, which was reconfirmed in in vivo mouse 
spindle skin cancer tumors, indicates the possible existence of an heterogenous population of 
GR isoforms and/or variants, some of which may have dominant negative function to the 
typical full-length isoforms. From the pathology point of view, this means that GR nuclear 
localization may not be a positive clinical indication for GC-responsiveness, as originally had 
been suggested 37, especially given the fact that several dominant negative GR isoforms or 
splice variants that antagonize functional, full-length GR, and cause GC-unresponsiveness 
are also localized in the nucleus.1,2These issues will be clarified in future studies. 
BrTaur, our first study case to be checked with our system, presents overlapping 
characteristics with GCs and is topically used in skin inflammatory conditions, such as acne 
vulgaris, instead of steroids 13. It is well-tolerated and presents insignificant side-effects.13,15 
BrTaur surrogated for the antiproliferative effect on GC-sensitive and GC-resistant cells, thus 
providing the first evidence for its potential to be used interchangeably to GCs in the context 
of cancer, in the same concept they are currently clinically used interchangeably to GCs in 
the context of chronic inflammations and microbial infections. The fact that BrTaur efficiently 
synergizes with cisplatin to inhibit growth of GC-resistant cells further highlights its GC-
mimicking therapeutic effect. The antiproliferative effect is strongly linked to the bromine 
moiety of the bromotaurine molecule and is mediated by inhibition of cell cycle in GC-
resistant cells. The ability of BrTaur to produce a more consistent anticancer effect than 
taurine could be explained by the fact that the former is the oxidizing form, while the latter is 
the maternal, reservoir substance, considered as a pro-drug. In detail, taurine is retained in 
several tissues, primarily in liver, and is recruited in tissues undergoing oxidative stress by 
topically-produced HOCl and HOBr to finally be oxidized to its effective taurine haloamine 
derivatives. These scavenge the toxicity of the excess HOCl and HOBr and pick up the torch 
of immunologic responses at the lesion sites, preventing inflammation and exerting anti-
microbial and oxidizing properties13. In this respect, the inconsistent efficacy of taurine versus 
N-bromotaurine on the different cell lines of the mouse carcinogenesis system may be due to 
fluctuated micro-concentrations of HOBr in each different cell line milieu, thus resulting to 
corresponding fluctuations in the concentration of the active BrTaur finally being formed.  
It should be noted that overproliferation in our system, as in actual tumors, is 
associated with deregulation of several main pathways in addition to GR transactivation 
impairment.19 These pathways, such as the ERα and AP-1 oncogenic pathways, crosstalk 
with GR since they are antagonized by its transrepression mode of action. Their progressive 
overactivation towards the aggressive stages in our system22,26,38 implies a dysfunctional GR 
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transrepression mode additionally to the demonstrated impairment of GR transactivation 
mode. Furthermore, the mixed cytoplasmic and nuclear signal detected in aggressive stages 
of skin cancer indicates the possible existence of a heterogeneous population of GR isoforms 
and/or variants, some of which may have dominant negative function to the typical full-length 
isoforms. This could be an additional reason for GR’s inability to transactivate its targets and, 
thus, to subsequently mediate the antiproliferative effects of GCs in GC-resistant cells. This 
would mean that multiple factors causing GC-resistance are possibly accumulating towards 
the most aggressive stages. Therefore, our system must not be seen as a model dedicated to 
the study of a single GC-resistance cause. Rather, it should be cautiously used as a tool kit 
for performing preliminary screenings in order to discriminate the alternative agents with no 
antiproliferative action from the ones with the potential to restore antiproliferative response in 
GC-resistant cells.  
Notably, although skin cancers are primarily associated with impairment of the GR/GC 
axis, they are not treated with GCs. Thus our model is not proposed as a means to spot GC-
substitutes against this cancer type. However, it is the demonstrated ability of this skin 
cancer-based artificial model to produce results that are extrapolated to several other types of 
epithelial cancers21, including the ones that are commonly treated with GCs, that gives this 
model an added value as an emerging generalized screening tool kit for identifying GC-
substitutes. Using this basal screening tool, substances that are suspected, based on medical 
experience in the clinic, to have overlapping profiles with GCs could be confirmed as GC-
substitutes before being repurposed for the management of cancer patients. Based on this 
screening tool, investigational N-bromotaurine was shown to act as a GC-substitute, while its 
effects where reproduced in cancer types that are commonly treated with GCs, such as the 
GC-resistant human breast and prostate cancer cell lines. Further confirmation of this anti-
tumor effect in experimental animals in future studies could accelerate subsequent 
repositioning of BrTaur for the management of clinical cancer patients. 
The point our approach highlights is that already-in-clinical-use compounds, able to 
consistently induce an antiproliferative phenotype in GC-resistant cells, even via molecular 
circuits which are currently as unknown to molecular biologists, as are unfamiliar to the GC-
resistant cancer cells themselves, warrant to be unveiled and considered as possible GC-
substitute therapeutic solutions. Analogous with what happens with newer generation 
antibiotics that catch the microbes unawares, the success of such compounds to startle 
cancer cells towards an antiproliferative direction may rely to their possible ability to act 
through pathways that the cancer cells have never been called to deactivate before in order 
to become aggressive. Such GC-substitutes may have the clinical potential to prolong 
disease free-survival, reduce tumor size, delay progression, mitigate side-effects and improve 
quality of life, in combination with well-established drugs, thus complying to the FDA’s 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
established guidelines on cancer clinical trial end-points. 
(http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf).  
Last but not least, burning issues regarding BrTaur mechanism of action are awaiting 
to be thoroughly addressed in future studies. Potential ways for its systemic administration in 
the context of cancer therapeutics should also be explored. Anti-inflammatory effects of 
BrTaur are mediated by modification of the IkappaBalpha, an NF-kappaB inhibitor39. This 
interaction could also underlie BrTaur antiproliferative effects on GC-resistant cells, given that 
NF-kappaB stands in the cross-roads between inflammation and cancer40 and is a crucial 
effector of GR-mediated tumor-suppressor effects2. Given the commonalities shared between 
anti-inflammatory and anti-cancer pathways, BrTaur may, at least in part, exert its anti-cancer 
action, in addition to its well-known anti-inflammatory properties13 by targeting common 
networks underlying both pathological entities17,18. Comprehensive, high-throughput analyses 
of the molecular and cellular changes and the transcriptional programs alterations triggered 
upon BrTaur treatment using state-of-the-art, multiomics approaches are anticipated to shed 
more light on this issue in the future. The full range of BrTaur functions might extend beyond 
interfering with GR-mediated pathways, and is currently under investigation. The role of 
BrTaur in cancer emerges as a subject of fruitful research and poses as a mysterious “black 
box”, the decoding of which might pave the way for next generation therapeutics. 
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FIGURE LEGENDS 
 
Figure 1: Estimation of responsiveness of cell lines of the mouse skin carcinogenesis model 
to GCs (dexamethasone) by crystal violet assays. (a) In the representative time point of 48h, 
the number of cells drastically decreases proportional to dexamethasone concentration in 
comparison with the untreated cells in the C5N cell line (expressed as ratio to untreated 
cells). In contrast, there is no change in cell numbers of dexamethasone-treated P6, B9, A5 
and CarB cells compared to their corresponding untreated controls, in any of the 
concentrations tested. (b) The profile of the antiproliferative action of GCs on the GC-
sensitive C5N cells over time, for each of the tested dexamethasone concentrations in 
comparison to a selected GC-resistant cell line P6. The experiments were performed in 
triplicates. 
   
Figure 2: GR is translocated in nucleus during transition from squamous to spindle stage of 
skin carcinogenesis. (a) GR protein expression levels of total (tGR), cytoplasmic (cGR) and 
nuclear (nGR) extracts of the mouse skin carcinogenesis model. (b) Western blot results 
indicate a switch in the cytoplasmic-to-nuclear GR ratio (cGR-to-nGR) during transition from 
squamous to spindle stage. (c) Immunocytochemistry analysis of the panel of mouse skin 
carcinogenesis model with anti-GR antibody revealed cytoplasmic staining in C5N, P6 and B9 
cells, and mixed cytoplasmic and nuclear staining in A5 and CarB cells. The black arrows 
indicate GR-stained nuclei. These immunocytochemical patterns were rather uniform in the 
above mentioned cell lines. (d) The immunofluorescence GR signal is cytoplasmic in the 
squamous B9 cells, but nuclear in the spindle A5 cells. (e) Immunohistochemistry using anti-
GR antibody in paraffin-embedded tissues isolated from the papilloma, squamous and 
spindle stage of the same chemically-induced tumor in one mouse revealed higher number of 
GR-stained nuclei in spindle cells in comparison with the corresponding papilloma and 
squamous stage. Each figure represents a 200x magnitude, whereas the upper-right boxes in 
each figure represent a 400x magnitude. The black boxes represent the magnified area. The 
black arrows indicate GR-stained nuclei.  
 
Figure 3: GR is DNA binding-competent but transactivation-incompetent in GC-resistant cell 
lines of the mouse skin carcinogenesis model. (a) Electrophoretic mobility shift assay in the 
GC-responsive C5N revealed binding activity of GR to glucocorticoid responsive elements 
(GRE) only upon dexamethasone (C5N+dex) treatment. (b) EMSA assay for GR using 
nuclear extracts demonstrated binding activity of GR to glucocorticoid responsive elements 
(GRE) of the GC-unresponsive P6, B9, A5 and CarB cells in the absence of dexamethasone 
signal. DNA binding increases directly proportional to the demonstrated nuclear GR protein 
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levels towards more aggressive cell lines. Specificity of the EMSA reaction is confirmed by 
supershift reactions in A5 (lane 6) cells using anti-GR antibody. (c)  Luciferase assays in the 
GC-sensitive and the GC-resistant cells of the mouse skin carcinogenesis model co-
transfected with the 17m-GRE-G-Luc, in dexamethasone absence (-dex) or presence (+dex). 
Luciferase expression is significantly induced (One asterisk (*) denotes p <0.05) only in the 
GC-sensitive C5N cells upon dexamethasone treatment. Error bars represent the standard 
error of the mean. Two-tailed p values are are derived from independent t-tests. Three 
biological replicates were available for each experiment. (d) Box plots demonstrating the 
transcription induction of GILZ under dexamethasone treatment in in the GC-sensitive and 
the GC-resistant cell lines before (-dex) and after (+dex) dexamethasone treatment, 
estimated by qPCR. The relative quantification (RQ) values in log10 are shown. For each cell 
line, the untreated control was used as calibrator. The housekeeping gene beta-2 
microglobulin was used as an internal control of mRNA Q-PCR expression. The experiments 
were performed in triplicates. (e) Same as 3d, for p57KIP2 mRNA levels. In both genes, 
significant induction is only observed in C5N cells (indicated by star). RQ: relative 
quantification value. 
 
 
Figure 4: Estimation of the antiproliferative response of the GC-sensitive and the GC-
resistant cell lines to N-bromotaurine by proliferation assays. (a) In the representative time 
point of 48h, the number of cells drastically decreases in comparison with the corresponding 
untreated control cells for all cell lines of the study model (expressed as ratio to untreated 
cells). (b) Comparative treatment of the cells with the maternal substance taurine did not 
affect mouse skin cancer cell proliferation in a significant and consistent manner, implying 
that bromination of the taurine is the crucial factor for the consistent antiproliferative effect on 
cells. (c) The profile of the antiproliferative action of N-bromotaurine on the GC-resistant GC-
resistant prostate cancer PC3. (d) Same as 4c for the human GC-resistant prostate cancer 
MDA-MB-231. The experiments were performed in triplicates. 
 
Figure 5: Comparison of the antiproliferative response of the aggressive GC-resistant cells to 
GCs versus N-bromotaurine. (a) proliferation assays on CarB cells treated with 
dexamethasone reveal lack of significant antiproliferative response of CarB upon addition of 
GCs over time, as evidenced by the OD measurements. (b) In contrast, proliferation assays 
on CarB cells treated with N-bromotaurine instead of dexamethasone reveal restoration of 
antiproliferative response of CarB cells by N-bromotaurine over time. The restoration of 
antiproliferative response is statistically significant in the 250μM concentration, after 48 and 
72 hours of N-bromotaurine treatment. Three independent experiments were performed, each 
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in triplicate. The means+SEM values are shown in the graphs. (c) FACS analysis of N-
bromotaurine-treated CarB cells (CarB + BrTaur) compared with dexamethasone-treated 
CarB cells (CarB + dex) and untreated CarB cells (CarB). BrTaur, at concentrations of 125μΜ 
and 250μΜ, increased the number of cells in G0/G1 phase; whereas at the high 
concentration of 500μΜ, BrTaur drastically decreased both G0/G1 and G2/M phases. 
Dexamethasone, at 10-7M concentration failed to significantly affect the number of cells in 
G1/G0 phase. Corresponding summary graphs for each phase of the cell cycle (means±SEM 
from 3 independent FACS analyses measurements) derived by comparison of untreated 
CarB cells each of the dexamethasone-treated, 125μΜ BrTaur-treated, 250μΜ BrTaur-
treated and 500μΜ BrTaur-treated CarB cells. (d-f) 250μΜ BrTaur-treated and 500μΜ 
BrTaur-treated CarB cells synergized efficiently with 2.9 cisplatin (cis) after 48hours of BrTaur 
plus cisplatin combination therapy as (d) pre-treament (BrTaur + cis), (e) concurrent 
treatment (cis/BrTaur) or (f) post-treatment (cis + BrTaur). Results are flagged with no 
asterisk when p-value is more than 0.05, and with two asterisks when the p-value is less than 
0.001.(See text for details on treatment schemes of 5d-f).  
 
 
Table I: Primers used for Q-PCR reactions 
Q-PCR amplicon Primers Primer sequence Annealing temperature 
p57KIP2 F 5- CCTCTTCGGGCCTGTAGAC -3  
 
59oC 
 R 5- CACCGTCTCGCGGTAGAA -3 
GILZ F 5-TAACACTGTCTGGTAACGATGTTAA-3 
 R 5-TAACACTGTCTGGTAACGATGTTAA-3 
β2-microglobulin F 5- GCATGGCTCGCTCGGTGAC -3 
 R 5- GGCGTATGTATCAGTCTCAGTG-3 
 
Table I
Table II: Mouse skin carcinogenesis model features, in correlation with aspects of 
GR status in each cell line of the model.  
    Model features 
 
 
GR features 
INITIATION PROMOTION PROGRESSION 
C5N P6 B9 A5 CarB 
GC-sensitive GC-
resistant 
GC-
resistant 
GC-
resistant 
GC-resistant 
EXPRESSION   
Nuclear GR levels + + ++ ++++ ++++ 
LOCALIZATION   
GR localization cyt cyt cyt nucl+cyt nucl+cyt 
DNA BINDING   
binding to GRE 
elements 
+ + ++ ++++ ++++ 
TRANSACTIVATION 
MODE 
  
Transactivation of GC-
responsive 
antiproliferative GRE-
containing targets 
+ - - - - 
Mutation in GR 
transactivation 
domains (exons 2, 5 
and 9) 
NO NO NO NO NO 
TRANSREPRESSION 
MODE 
  
Active AP-1 pathway38 + ++ +++ ++++ ++++ 
Active ERα pathway22 + ++ ++++ ++++ ++++ 
 
cyt: cytoplasmic; nucl: nuclear 
The bold line of the table represents the threshold between promotion and 
progression stages in the mouse skin carcinogenesis system. 
 
Table II
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